The possible connection of NAION with tirzepatide-containing drugs Mounjaro and Zepbound is being investigated by the FDA, according to “October – December 2024 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)”.
During the past year, we have written about the vision loss side effect NAION (non-arteritic anterior ischemic optic neuropathy) being linked to semaglutide-containing drugs Ozempic, Rybelsus, and Wegovy. This is our first article about the possible connection of NAION with tirzepatide-containing drugs Mounjaro and Zepbound.
We will watch for developments concerning the possible connection of NAION with tirzepatide-containing drugs Mounjaro and Zepbound.
If you have developed NAION with Mounjaro or Zepbound, there might be a drug injury lawsuit against the responsible pharmaceutical company. Please don’t hesitate to contact us if you are interested in such a case.
[Read the article in full at source]Mounjaro / Zepbound
Free Case Evaluation
Strictly Confidential, No Obligation